{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:56Z","timestamp":1789398176002,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sun Pharma Laboratories Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00544-y","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:38:50Z","timestamp":1774597130000},"page":"513-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0226-8901","authenticated-orcid":false,"given":"Yogesh","family":"Garje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanish","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudit","family":"Sabharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-6134","authenticated-orcid":false,"given":"Ashwini","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2249-2662","authenticated-orcid":false,"given":"Shruti","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6300-6665","authenticated-orcid":false,"given":"Neeraj","family":"Markandeywar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5632-7181","authenticated-orcid":false,"given":"Chintan","family":"Khandhedia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-4693","authenticated-orcid":false,"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7553-4128","authenticated-orcid":false,"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-4942","authenticated-orcid":false,"given":"Sadhna","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"3","key":"544_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/ecp.09.8","volume":"2","author":"A Mejia","year":"2009","unstructured":"Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2(3):295\u2013314.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"544_CR2","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20164779","volume":"6","author":"RR Rai","year":"2016","unstructured":"Rai RR, Gangadhar A, Mayabhate MM. Clinical profiling of patients with acid peptic disorders (APD) in India: a cross-sectional survey of clinicians. Int J Basic Clin Pharmacol. 2016;6(1):194.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"544_CR3","doi-asserted-by":"crossref","unstructured":"Jain S, Kulkarni SS, Mahapatra JR, Todi D, Petare AU, Banerjee R, et al. Effectiveness of omeprazole in acid peptic disease: a real-world, patient-reported outcome measures study. Cureus. 2023;15(7).","DOI":"10.7759\/cureus.41994"},{"key":"544_CR4","unstructured":"Medindia. Acid Peptic Disease. 2021. https:\/\/www.medindia.net\/health\/conditions\/acid-peptic-disease.htm."},{"key":"544_CR5","unstructured":"Laboratories DRs. An approach to APD and its management. 2023. p. 46."},{"key":"544_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11081085","author":"J Sun","year":"2023","unstructured":"Sun J, Huang L, Li R, Wang T, Wang S, Yu C, et al. Comparison of secular trends in peptic ulcer diseases mortality in China, Brazil and India during 1990\u20132019: an age-period-cohort analysis. Healthcare. 2023. https:\/\/doi.org\/10.3390\/healthcare11081085.","journal-title":"Healthcare"},{"key":"544_CR7","doi-asserted-by":"crossref","unstructured":"7.RameshRoopRai AG, Mayur M. Mayabhate. Clinical profiling of patients with Acid Peptic Disorders (APD) in India: a cross-sectional survey of clinicians. Int J Basic Clin Pharmacol. 2017;6(1).","DOI":"10.18203\/2319-2003.ijbcp20164779"},{"issue":"4","key":"544_CR8","first-page":"998","volume":"5","author":"MB Manohar Shankarrao Chavan","year":"2018","unstructured":"Manohar Shankarrao Chavan MB. Prevalence and risk factors of acid peptic ulcer disease at a tertiary care hospital. Int J Adv Med. 2018;5(4):998\u20131002.","journal-title":"Int J Adv Med"},{"issue":"1","key":"544_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.18203\/2319-2003.ijbcp20164779","volume":"6","author":"RR Rai","year":"2017","unstructured":"Rai RR, Gangadhar A, Mayabhate MM. Clinical profiling of patients with acid peptic disorders (APD) in India: a cross-sectional survey of clinicians. Int J Basic Clin Pharmacol. 2017;6(1):194\u2013202.","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"2","key":"544_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/00365521.2014.983157","volume":"50","author":"S Rasmussen","year":"2015","unstructured":"Rasmussen S, Jensen TH, Henriksen SL, Haastrup PF, Larsen PV, Sondergaard J, et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"544_CR11","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20183134","volume":"5","author":"MS Chavan","year":"2018","unstructured":"Chavan MS, Bhaktavatsalam M. Prevalence and risk factors of acid peptic ulcer disease at a tertiary care hospital. Int J Adv Med. 2018;5(4):988.","journal-title":"Int J Adv Med"},{"issue":"Suppl 12","key":"544_CR12","doi-asserted-by":"publisher","first-page":"S1594","DOI":"10.21037\/jtd.2019.06.42","volume":"11","author":"C Newberry","year":"2019","unstructured":"Newberry C, Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J Thorac Dis. 2019;11(Suppl 12):S1594\u2013601.","journal-title":"J Thorac Dis"},{"issue":"1","key":"544_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0149-2918(96)80175-5","volume":"18","author":"SW Sanders","year":"1996","unstructured":"Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther. 1996;18(1):2\u201334.","journal-title":"Clin Ther"},{"issue":"1","key":"544_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","volume":"25","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25(1):6\u201314.","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"544_CR15","first-page":"273","volume":"66","author":"BT Vanderhoff","year":"2002","unstructured":"Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273\u201380.","journal-title":"Am Fam Physician"},{"issue":"2","key":"544_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","volume":"123","author":"PF Haastrup","year":"2018","unstructured":"Haastrup PF, Thompson W, Sondergaard J, Jarbol DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123(2):114\u201321.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"544_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"544_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308\u201328 (quiz 29).","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"544_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706\u201315.","journal-title":"Gastroenterology"},{"issue":"4","key":"544_CR20","first-page":"88","volume":"67","author":"S Bhatia","year":"2019","unstructured":"Bhatia S, Shukla A, Johnson D, Thatte U, Lawate P, Babu S, et al. An expert review and recommendations on the rational use of proton pump inhibitors: Indian perspective. J Assoc Physicians India. 2019;67(4):88\u201396.","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"544_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"CGL Scarpignato","year":"2016","unstructured":"Scarpignato CGL, Zullo A, Blandizzi C, Scarpignato C, Blandizzi C, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases\u2014a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.","journal-title":"BMC Med"},{"issue":"7","key":"544_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07595","volume":"7","author":"RM RhA","year":"2021","unstructured":"RhA RM. The inappropriate use of proton pump inhibitors and its associated factors among community-dwelling older adults. Heliyon. 2021;7(7):e07595.","journal-title":"Heliyon."},{"issue":"23 Suppl 4","key":"544_CR23","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1093\/ajhp\/56.suppl_4.S11","volume":"56","author":"JP Reilly","year":"1999","unstructured":"Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23 Suppl 4):S11\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"544_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5009\/gnl16352","volume":"11","author":"YJKN Choi","year":"2017","unstructured":"Choi YJKN, Jang I-J, Cho J-Y, Nam RH, Park JH, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504\u201311.","journal-title":"Gut Liver."},{"issue":"4","key":"544_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"RS Wedemeyer","year":"2014","unstructured":"Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201\u201311.","journal-title":"Drug Saf"},{"issue":"7","key":"544_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19818","volume":"7","author":"CM Tan","year":"2024","unstructured":"Tan CM, Juurlink DN. Navigating drug interactions with proton pump inhibitors. JAMA Netw Open. 2024;7(7):e2419818.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"544_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1365-2125.2006.02687.x","volume":"62","author":"GCS Trifir\u00f2","year":"2006","unstructured":"Trifir\u00f2 GCS, Alacqua M, Moretti S, Tari M, Caputi AP, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol. 2006;62(5):582\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"544_CR28","first-page":"2174","volume":"11","author":"S Shastry","year":"2020","unstructured":"Shastry S. Drug utilisation and evaluation of proton pump inhibitors in general medicine ward of a tertiary care hospital. J Pharm Sci Res. 2020;11(6):2174\u20139.","journal-title":"J Pharm Sci Res"},{"issue":"2","key":"544_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0018578719873876","volume":"56","author":"A Lavu","year":"2021","unstructured":"Lavu A, Ansari M, Acharya R, Vilakkathala R. A cross-sectional study on single-day use of proton pump inhibitors in tertiary care hospitals of South India. Hosp Pharm. 2021;56(2):109\u201315.","journal-title":"Hosp Pharm"},{"key":"544_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215469","author":"H Helgadottir","year":"2019","unstructured":"Helgadottir H, Bjornsson ES. Problems associated with deprescribing of proton pump inhibitors. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20215469.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"544_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.31254\/jsir.2016.5201","volume":"5","author":"KKDPSV Jha","year":"2016","unstructured":"Jha KKDPSV, Reddy V, Binu KM, Doddayya H. Prescribing pattern of acid suppressant drugs in current clinical practice. J Sci Innov Res. 2016;5(2):32\u20135.","journal-title":"J Sci Innov Res"},{"issue":"1","key":"544_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.47583\/ijpsrr.2021.v66i01.009","volume":"66","author":"MKJF Manu","year":"2021","unstructured":"Manu MKJF, Rao KM, Chetty DS, Surendranath DA, Musthafa DF. Prospective assessment of prescribing pattern of proton pump inhibitors in a tertiary care hospital in Chennai. Int J Pharm Sci Rev Res. 2021;66(1):38\u201342.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"5","key":"544_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3748\/wjg.14.709","volume":"14","author":"X Wang","year":"2008","unstructured":"Wang X, Pitchumoni CS, Chandrarana K, Shah N. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol. 2008;14(5):709\u201312.","journal-title":"World J Gastroenterol"},{"key":"544_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/life13051107","author":"M Floria","year":"2023","unstructured":"Floria M, Iov DE, Tanase DM, Barboi OB, Baroi GL, Burlacu A, et al. Gastro-esophageal reflux disease and paroxysmal atrial fibrillation ablation. Life (Basel). 2023. https:\/\/doi.org\/10.3390\/life13051107.","journal-title":"Life (Basel)"},{"key":"544_CR35","doi-asserted-by":"publisher","first-page":"A9213","DOI":"10.1161\/circ.124.suppl_21.A9213","volume":"124","author":"MYF Lalibert\u00e9","year":"2011","unstructured":"Lalibert\u00e9 MYF, Dea K, LaMori JC, Mody SH, Jones JL, et al. Abstract 9213: risk of gastrointestinal conditions among patients with atrial fibrillation. Circulation. 2011;124:A9213-A.","journal-title":"Circulation"},{"issue":"1","key":"544_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.25100\/cm.v44i1.1028","volume":"44","author":"J Machado-Alba","year":"2013","unstructured":"Machado-Alba J, Fernandez A, Castrillon JD, Campo CF, Echeverri LF, Gaviria A, et al. Prescribing patterns and economic costs of proton pump inhibitors in Colombia. Colomb Med (Cali). 2013;44(1):13\u20138.","journal-title":"Colomb Med (Cali)"},{"issue":"2","key":"544_CR37","volume":"14","author":"H Saven","year":"2022","unstructured":"Saven H, Zhong L, McFarlane IM. Co-prescription of dual-antiplatelet therapy and proton pump inhibitors: current guidelines. Cureus. 2022;14(2):e21885.","journal-title":"Cureus"},{"issue":"1","key":"544_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1086-5802(16)31036-1","volume":"40","author":"LS Welage","year":"2000","unstructured":"Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40(1):52\u201362 (quiz 121\u2013123).","journal-title":"J Am Pharm Assoc (Wash)."},{"issue":"3","key":"544_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/mamcjms.mamcjms_40_19","volume":"5","author":"NTV Verma","year":"2019","unstructured":"Verma NTV, Roy V. Proton pump inhibitors: prescribing practices, appropriateness of use, and cost incurred in a tertiary care, public, teaching hospital in New Delhi, India. MAMC J Med Sci. 2019;5(3):113\u201320.","journal-title":"MAMC J Med Sci"},{"issue":"11","key":"544_CR40","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0149-2918(00)83025-8","volume":"22","author":"PW Jungnickel","year":"2000","unstructured":"Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther. 2000;22(11):1268\u201393.","journal-title":"Clin Ther"},{"issue":"3","key":"544_CR41","first-page":"203","volume":"69","author":"UA Meyer","year":"1996","unstructured":"Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996;69(3):203\u20139.","journal-title":"Yale J Biol Med"},{"key":"544_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-2-17","volume":"2","author":"M Salas","year":"2002","unstructured":"Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol. 2002;2:17.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"544_CR43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11377-017-0222-9","volume":"13","author":"A Dabrowski","year":"2018","unstructured":"Dabrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease\u2014PAN-STAR. Prz Gastroenterol. 2018;13(1):6\u201315.","journal-title":"Prz Gastroenterol"},{"issue":"1","key":"544_CR44","volume":"13","author":"M Yibirin","year":"2021","unstructured":"Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1):e12759.","journal-title":"Cureus"},{"issue":"4","key":"544_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00002018-200225040-00005","volume":"25","author":"AA Claessens","year":"2002","unstructured":"Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study. Drug Saf. 2002;25(4):287\u201395.","journal-title":"Drug Saf"}],"updated-by":[{"DOI":"10.1007\/s40801-026-00569-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000}}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00544-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:05:17Z","timestamp":1789394717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00544-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00544-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"11 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: \"The Conflict of Interest (CoI) statement and ORCID IDs of the authors are updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40801-026-00569-3","URL":"https:\/\/doi.org\/10.1007\/s40801-026-00569-3","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shruti Dharmadhikari, Dr. Neeraj Markandeywar, Dr. Chintan Khandhedia, Dr. Amey Mane and Dr. Suyog Mehta are employees of Sun Pharma Laboratories Ltd, Mumbai, Maharashtra, India. Dr. Ashwini Satpathy and Dr. Yogesh Garje are ex-employees of Sun Pharma Laboratories Ltd, Mumbai, Maharashtra, India. Dr. Sadhna Joglekar was an employee at Sun Pharma Laboratories Ltd during the conduct of this study. She is currently employed with Novartis. The views expressed in the article are author\u2019s views and do not necessarily reflect the views or official position of Novartis. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted as per the Declaration of Helsinki. The study was approved by the Royal Pune Independent Ethics Committee (RPIEC) located in Pune, India (ethics approval number: RPIEC100321; dated 15th March 2021).","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study used anonymized data without additional prospective components for research purposes. Hence, obtaining informed consent from patients was not required for this study, as it did not involve identifiable individuals. Accordingly, IEC\u2019s permission for an informed consent waiver was obtained.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: YG, TM, MS, SG, RS. Methodology: YG, TM, MS, SG, RS. Visualization: YG, TM, MS, SG, RS, AS, SD, NM, CK, AM, SM, SJ. Resources, data curation, project administration, investigation: TM, MS, SG, RS. Supervision: TM, MS, SG, RS, AS, SD, NM, CK, AM, SM, SJ. Writing\u2014review and editing: YG, TM, MS, SG, RS, AS, SD, NM, CK, AM, SM, SJ. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}